Abstract
Rationale
The results from case–control and retrospective studies revealed that olanzapine might be associated with more increased risks of metabolic dysfunction than risperidone. The crossover design can minimize the influence of individual variation in metabolic profiles and demographic variables, such as age, sex, concomitant medication use and personal life styles.
Objectives
We design a crossover study to evaluate the metabolic effect of olanzapine and risperidone.
Methods
Fifteen schizophrenic patients were shifted from olanzapine and risperidone or from risperidone and olanzapine due to poor treatment response. The body weights, lipid profiles and fasting glucose levels were assessed before medication switch and 3 months after crossover.
Results
In the seven patients taking risperidone at the time of inclusion (risperidone-first group), after shifting to olanzapine, there was a significant increase in triglyceride level (p=0.048) and body weight (p=0.008). In the other eight patients (olanzapine-first group), after shift to risperidone, there was a decrease in triglyceride level (p=0.009), body weight (p=0.049) and body mass index (BMI; p=0.04). When comparing the metabolic profiles in all patients after olanzapine and after risperidone (irrespective of the order of treatment), the mean triglyceride level (p=0.001), body weight (p=0.001) and BMI (p=0.015) were significantly higher in patients receiving olanzapine than in those receiving risperidone. Furthermore, there was a small increase in total cholesterol level (p=0.091) and a small decrease in high-density lipoprotein (HDL) level (p=0.061) in olanzapine group, but the differences did not reach a significant level. There was no significant difference between olanzapine and risperidone in fasting glucose and low-density lipoprotein (LDL).
Conclusions
This study confirms that elevated levels of triglyceride and body weight could be associated with the use of olanzapine as compared with risperidone. The changes in body weights and lipid profiles should be closely monitored in patients during treatment with atypical antipsychotic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601
Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598–604
Castelli WP (1986) The triglyceride issue: a view from Framingham. Am Heart J 112:432–437
Ghaeli P, Dufresne RL (1999) Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 19:1099–1101
Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360–372
Itoh T, Horie S, Takahashi K, Okubo T (1996) An evaluation of various indices of body weight change and their relationship with coronary risk factors. Int J Obes Relat Metab Disord 20:1089–1096
Koro CE, Meyer JM (2005) Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol 6:148–157
Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021–1026
Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986) Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2:933–936
McIntyre RS, McCann SM, Kennedy SH (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46:273–281
Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742–749
Melkersson KI, Dahl ML, Hulting AL (2004) Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose–insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 175(1):1–6
Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425–433
Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17
O'Neil MJ, Smith A, Heckelman PE, Kinneary JF, Budavari S (2001) The Merck index: an encyclopedia of chemicals, drugs and biologicals, 13 edn. Merck & Co., Whitehouse Station, NJ
Osser DN, Najarian DM, Dufresne RL (1999) Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767–770
Ried LD, Renner BT, Bengtson MA, Wilcox BM, Acholonu WW Jr (2003) Weight change after an atypical antipsychotic switch. Ann Pharmacother 37:1381–1386
Su KP, Shen WW, Huang SY (2001) Lipid abnormalities induced by novel antipsychotic drugs. Drug Saf 24:1017–1018
Su KP, Shen WW, Chuang CL, Chen KP, Chen CC (2003) A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol. Schizophr Res 59:93–94
Van Gaal LF, Zhang A, Steijaert MM, De Leeuw IH (1995) Human obesity: from lipid abnormalities to lipid oxidation. Int J Obes Relat Metab Disord 19(Suppl 3):S21–S26
Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856–865
Wu BL, Lane HY, Su KP. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus. Psychiatry Clin Neurosci, in press
Yanovski JA, Yanovski SZ (1999) Recent advances in basic obesity research. JAMA 282:1504–1506
Acknowledgements
The work was supported by grants DOH 94F044, DMR-92-017 and CMU93-M-24 from the Department of Health, the China Medical University Hospital in Taiwan. This study received no financial support from any pharmaceutical industry.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Su, KP., Wu, PL. & Pariante, C.M. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology 183, 383–386 (2005). https://doi.org/10.1007/s00213-005-0205-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-0205-2